Carlos Juan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3066822/publications.pdf

Version: 2024-02-01

82	5,431	66343	85541
papers	citations	42	71
		h-index	g-index

88	88	88	4767
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. Journal of Antimicrobial Chemotherapy, 2022, 77, 957-968.	3.0	14
2	Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrugâ€resistant <scp>Gram</scp>â€negatives. Biological Reviews, 2022, 97, 1005-1037.	10.4	5
3	Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired Î²-Lactamases on Pseudomonas aeruginosa Virulence. Microbiology Spectrum, 2022, 10, e0201921.	3.0	8
4	6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to Î²-Lactam Antibiotics. Journal of Medicinal Chemistry, 2021, 64, 6310-6328.	6.4	10
5	Pathogenic characteristics of Pseudomonas aeruginosa bacteraemia isolates in a high-endemicity setting for ST175 and ST235 high-risk clones. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 671-678.	2.9	15
6	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 2508-2515.	3.0	24
7	Activity of mammalian peptidoglycan-targeting immunity against Pseudomonas aeruginosa. Journal of Medical Microbiology, 2020, 69, 492-504.	1.8	5
8	In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wallâ€“Targeting Immunity. Journal of Infectious Diseases, 2019, 220, 1729-1737.	4.0	18
9	Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections. Frontiers in Microbiology, 2019, 10, 1868.	3.5	12
10	Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins. Scientific Reports, 2019, 9, 3575.	3.3	10
11	Regulation of AmpC-Driven Î²-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling. MSystems, 2019, 4, .	3.8	53
12	Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 623-625.	0.3	0
13	Optimizing the management of Pseudomonas aeruginosa infections with tools for the detection of resistance mechanisms and pharmacokinetic/pharmacodynamic (PK/PD) analysis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 623-625.	0.5	1
14	Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 658-663.	3.0	157
15	Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens. Microbiology and Molecular Biology Reviews, 2018, 82, .	6.6	36
16	Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model. International Journal of Antimicrobial Agents, 2017, 49, 198-203.	2.5	12
17	Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections. Journal of Infectious Diseases, 2017, 215, S44-S51.	4.0	116
18	Synergistic activity of fosfomycin, Î²-lactams and peptidoglycan recycling inhibition againstPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2017, 72, 448-454.	3.0	25

#	Article	IF	Citations
19	Diversity and regulation of intrinsic Î²-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS Microbiology Reviews, 2017, 41, 781-815.	8.6	83
20	Sensing Mg²⁺ contributes to the resistance of Pseudomonas aeruginosa to complementâ€mediated opsonophagocytosis. Environmental Microbiology, 2017, 19, 4278-4286.	3.8	20
21	In Vivo Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	61
22	Synthesis and Antimicrobial Studies of New Antibacterial Azo-Compounds Active against Staphylococcus aureus and Listeria monocytogenes. Molecules, 2017, 22, 1372.	3.8	37
23	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system. PLoS ONE, 2017, 12, e0181932.	2.5	32
24	Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. International Journal of Antimicrobial Agents, 2016, 47, 368-374.	2.5	30
25	Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	3.2	99
26	Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?. MBio, 2016, 7, .	4.1	62
27	Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 195-200.	2.9	21
28	VIM-47, a New Variant of the Autochthonous Metallo-Î²-Lactamase VIM-13 from the Balearic Islands in Spain. Antimicrobial Agents and Chemotherapy, 2016, 60, 3251-3252.	3.2	3
29	Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1767-1778.	3.2	170
30	Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC Î²-Lactamases or Carbapenemases from Enterobacteriaceae: Findings from a Multicenter Study in Spain. Antimicrobial Agents and Chemotherapy, 2015, 59, 5260-5266.	3.2	19
31	The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates, 2015, 21-22, 41-59.	14.4	475
32	Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo-Î²-Lactamase-Producing Pseudomonas spp. Antimicrobial Agents and Chemotherapy, 2014, 58, 4992-4992.	3.2	1
33	Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. Antimicrobial Agents and Chemotherapy, 2014, 58, 3091-3099.	3.2	197
34	Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo-Î²-Lactamase-Producing Pseudomonas spp. Antimicrobial Agents and Chemotherapy, 2014, 58, 2454-2458.	3.2	11
35	Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. International Journal of Medical Microbiology, 2014, 304, 1182-1191.	3.6	30
36	The Pseudomonas aeruginosa CreBC Two-Component System Plays a Major Role in the Response to Î²-Lactams, Fitness, Biofilm Growth, and Global Regulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 5084-5095.	3.2	56

#	Article	IF	Citations
37	Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain. Genome Announcements, 2014, 2, .	0.8	4
38	Structure and interaction with phospholipids of a prokaryotic lipoxygenase from Pseudomonas aeruginosa. FASEB Journal, 2013, 27, 4811-4821.	0.5	78
39	First detection in Europe of the metallo-Î²-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa. Clinical Microbiology and Infection, 2013, 19, E424-E427.	6.0	27
40	Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone. Genome Announcements, 2013, 1, e0011213.	0.8	9
41	Challenges for accurate susceptibility testing, detection and interpretation of Â-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study. Journal of Antimicrobial Chemotherapy, 2013, 68, 619-630.	3.0	20
42	Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2013, 57, 5527-5535.	3.2	104
43	Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2012, 56, 6349-6357.	3.2	189
44	Transferable Multidrug Resistance Plasmid Carrying cfr Associated with tet (L), ant(4 â€²)-Ia , and dfrK Genes from a Clinical Methicillin-Resistant Staphylococcus aureus ST125 Strain. Antimicrobial Agents and Chemotherapy, 2012, 56, 2139-2142.	3.2	47
45	Pan-Î²-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. Antimicrobial Agents and Chemotherapy, 2012, 56, 4771-4778.	3.2	138
46	Unusual Diversity of Acquired Î²-lactamases in Multidrug-ResistantPseudomonas aeruginosaIsolates in a Mexican Hospital. Microbial Drug Resistance, 2012, 18, 471-478.	2.0	15
47	VIM-2â€“producing Multidrug-ResistantPseudomonas aeruginosaST175 Clone, Spain. Emerging Infectious Diseases, 2012, 18, 1235-41.	4.3	59
48	Unmanageable norovirus outbreak in a single resort located in the Dominican Republic. Clinical Microbiology and Infection, 2011, 17, 952-954.	6.0	18
49	A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infectious Diseases, 2011, 11, 272.	2.9	54
50	Role of Klebsiella pneumoniae LamB Porin in Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2011, 55, 1803-1805.	3.2	87
51	OmpK26, a Novel Porin Associated with Carbapenem Resistance in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2011, 55, 4742-4747.	3.2	56
52	Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. Antimicrobial Agents and Chemotherapy, 2011, 55, 4560-4568.	3.2	58
53	Environmental Microbiota Represents a Natural Reservoir for Dissemination of Clinically Relevant Metallo-Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2011, 55, 5376-5379.	3.2	55
54	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial Chemotherapy, 2011, 66, 2022-2027.	3.0	132

#	Article	IF	Citations
55	AmpG Inactivation Restores Susceptibility of Pan-Î²-Lactam-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 1990-1996.	3.2	47
56	Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-Â-lactamases–authors' response. Journal of Antimicrobial Chemotherapy, 2011, 66, 686-686.	3.0	4
57	Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clinical Microbiology and Infection, 2010, 16, 1482-1487.	6.0	31
58	NagZ Inactivation Prevents and Reverts Î²-Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2010, 54, 3557-3563.	3.2	61
59	Differential Â-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. Journal of Antimicrobial Chemotherapy, 2010, 65, 1540-1542.	3.0	42
60	Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-Â-lactamases. Journal of Antimicrobial Chemotherapy, 2010, 65, 1950-1954.	3.0	29
61	Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2010, 54, 3933-3937.	3.2	88
62	Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2010, 54, 846-851.	3.2	85
63	Activity of a New Cephalosporin, CXA-101 (FR264205), against Î²-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 1213-1217.	3.2	96
64	Metallo-Â-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. Journal of Antimicrobial Chemotherapy, 2010, 65, 474-478.	3.0	105
65	Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible Pseudomonas aeruginosa Strain Overexpressing MexXY-OprM and Producing an Integron-Borne PSE-1 ÃŸ-Lactamase. Journal of Clinical Microbiology, 2009, 47, 2381-2387.	3.9	35
66	Gastroenteritis Outbreaks in 2 Tourist Resorts, Dominican Republic. Emerging Infectious Diseases, 2009, 15, 1877-1878.	4.3	14
67	Î²-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. PLoS Pathogens, 2009, 5, e1000353.	4.7	258
68	Azithromycin in Pseudomonas aeruginosa Biofilms: Bactericidal Activity and Selection of nfxB Mutants. Antimicrobial Agents and Chemotherapy, 2009, 53, 1552-1560.	3.2	73
69	Detection of the Novel Extended-Spectrum Î²-Lactamase OXA-161 from a Plasmid-Located Integron inPseudomonas aeruginosaClinical Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 5288-5290.	3.2	25
70	Extended-spectrum Î²-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International Journal of Antimicrobial Agents, 2009, 34, 173-176.	2.5	164
71	Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 Pseudomonas aeruginosa Isolates Producing the Extended-Spectrum Î²-Lactamases GES-1 and GES-5 in Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 4930-4933.	3.2	91
72	Benefit of Having MultipleampDGenes for Acquiring Î²-Lactam Resistance without Losing Fitness and Virulence inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2008, 52, 3694-3700.	3.2	91

#	Article	IF	Citations
73	Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2008, 63, 60-66.	3.0	66
74	Chronic Respiratory Infections by Mucoid Carbapenemase-Producing Pseudomonas aeruginosa Strains, a New Potential Public Health Problem. Antimicrobial Agents and Chemotherapy, 2008, 52, 2285-2286.	3.2	12
75	Characterization of the New Metallo-Î²-Lactamase VIM-13 and Its Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in Spain. Antimicrobial Agents and Chemotherapy, 2008, 52, 3589-3596.	3.2	71
76	Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa Isolates from Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2007, 51, 4329-4335.	3.2	161
77	PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Molecular Microbiology, 2006, 62, 84-99.	2.5	97
78	Stepwise Upregulation of the Pseudomonas aeruginosa Chromosomal Cephalosporinase Conferring High-Level Î²-Lactam Resistance Involves Three AmpD Homologues. Antimicrobial Agents and Chemotherapy, 2006, 50, 1780-1787.	3.2	164
79	Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clinical Microbiology and Infection, 2005, 11, 887-892.	6.0	38
80	Molecular Mechanisms of Î²-Lactam Resistance Mediated by AmpC Hyperproduction in Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2005, 49, 4733-4738.	3.2	146
81	Lack of Association between Hypermutation and Antibiotic Resistance Development in Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 3573-3575.	3.2	60
82	Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. Antimicrobial Agents and Chemotherapy, 2004, 48, 4226-4233.	3.2	138